Search Results - Francesco Passiglia
- Showing 1 - 20 results of 27
- Go to Next Page
-
1
-
2
-
3
Looking for the best immune‐checkpoint inhibitor in pre‐treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab by Francesco Passiglia, Antonio Galvano, Sérgio Rizzo, Lorena Incorvaia, Angela Listì, Viviana Bazan, Antonio Russo
Published 2017Revisão -
4
-
5
-
6
-
7
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis by Francesco Passiglia, Giuseppe Bronte, Viviana Bazan, Clara Natoli, Sérgio Rizzo, Antonio Galvano, Angela Listì, Giuseppe Cicero, Christian Rolfo, Daniele Santini, Antonio Russo
Published 2016Artigo -
8
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis by Francesco Passiglia, Sérgio Rizzo, Massimo Di Maïo, Antonio Galvano, Giuseppe Badalamenti, Angela Listì, Leonardo Gulotta, Marta Castiglia, Fabio Fulfaro, Viviana Bazan, Antonio Russo
Published 2018Revisão -
9
-
10
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS? by Giuseppe Bronte, Nicola Silvestris, Marta Castiglia, Antonio Galvano, Francesco Passiglia, Giovanni Sortino, Giuseppe Cicero, Christian Rolfo, Marc Peeters, Viviana Bazan, Daniele Fanale, Antonio Giordano, Antonio Russo
Published 2015Revisão -
11
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients by Francesco Passiglia, Antonio Galvano, Marta Castiglia, Lorena Incorvaia, Valentina Calò, Angela Listì, Salvatore Mazzarisi, Alessandro Perez, Giuseppe Gallina, Sérgio Rizzo, Héctor Soto Parrà, Viviana Bazan, Antonio Russo
Published 2019Artigo -
12
Liquid biopsies in lung cancer: The new ambrosia of researchers by Christian Rolfo, Marta Castiglia, David S. Hong, Riccardo Alessandro, Inge Mertens, Geert Baggerman, Karen Zwaenepoel, Ignacio Gil‐Bazo, Francesco Passiglia, Anna Paola Carreca, Simona Taverna, Renza Vento, Marc Peeters, Antonio Russo, Patrick Pauwels
Published 2014Revisão -
13
The evolving landscape of stage III unresectable non-small cell lung cancer “between lights and shadows” by Marco Donatello Delcuratolo, Veronica Crespi, Giorgio Saba, Andrea Mogavero, Valerio Maria Napoli, Edoardo Garbo, Massimiliano Cani, Antonio Ungaro, Maria Lucia Reale, Alessandra Merlini, Enrica Capelletto, Paolo Bironzo, Mario Levis, Umberto Ricardi, Silvia Novello, Francesco Passiglia
Published 2025Revisão -
14
Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option? by Daniele Fanale, Giuseppe Bronte, Francesco Passiglia, Valentina Calò, Marta Castiglia, F. Di Piazza, Nadia Barraco, Antonina Cangemi, Maria Teresa Catarella, Lavinia Insalaco, Angela Listì, R. Maragliano, Daniela Massihnia, Alessandro Perez, Francesca Toia, Giuseppe Cicero, Viviana Bazan
Published 2015Revisão -
15
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors by Christian Rolfo, Elisa Giovannetti, David S. Hong, Trever G. Bivona, Luis E. Raez, Giuseppe Bronte, L Buffoni, Noemı́ Reguart, Edgardo S. Santos, Paul Germonpré, Miquel Tarón, Francesco Passiglia, Jan P. van Meerbeeck, Antonio Russo, Marc Peeters, Ignacio Gil‐Bazo, Patrick Pauwels, Rafael Rosell
Published 2014Revisão -
16
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations by Francesco Passiglia, Federico Cappuzzo, Oscar Alabiso, Anna Bettini, Paolo Bidoli, Rita Chiari, Carlotta Defferrari, Angelo Delmonte, Giovanna Finocchiaro, Guido Francini, Francesco Gelsomino, Diana Giannarelli, Monica Giordano, Alfonso Illiano, Lorenzo Livi, Olga Martelli, Clara Natoli, Gianfranco Puppo, Enrico Ricevuto, Elisa Roca, D. Turci, Domenico Galetta
Published 2018Artigo -
17
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations by Jordi Remón, Francesco Passiglia, Myung‐Ju Ahn, Fabrice Barlési, Patrick M. Forde, Edward B. Garon, Scott Gettinger, Sarah B. Goldberg, Roy S. Herbst, Leora Horn, Kaoru Kubota, Shun Lü, Laura Mezquita, Luis Paz‐Ares, Sanjay Popat, Kurt A. Schalper, Ferdinandos Skoulidis, Martin Reck, Alex A. Adjei, Giorgio V. Scagliotti
Published 2020Revisão -
18
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab by Carlo Genova, Silvia Marconi, Giovanna Chiorino, Francesca Guana, Paola Ostano, Sara Santamaria, Giovanni Rossi, Irene Vanni, Luca Longo, Marco Tagliamento, Lodovica Zullo, Maria Giovanna Dal Bello, Chiara Dellepiane, Angela Alama, Erika Rijavec, Vienna Ludovini, Giulia Barletta, Francesco Passiglia, Giulio Metro, Sara Baglivo, Rita Chiari, Licia Rivoltini, Federica Biello, Iosune Baraibar, Ignacio Gil‐Bazo, Silvia Novello, Francesco Grossi, Simona Coco
Published 2024Artigo -
19
Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer by Veronica Crespi, Marco Donatello Delcuratolo, Gabriele Minuti, Michele Montrone, Sara Pilotto, Elisa Roca, Giulio Metro, Alessandro Leonetti, Giacomo Pelizzari, Carlo Genova, Emanuela Olmetto, Diego Cortinovis, Alessandro Russo, Giulia Pasello, Alessandra Bulotta, Francesco Grossi, Roberta Buosi, Alessandro Del Conte, Claudio Sini, Carlo Greco, Alessandro Morabito, Daniele Pignataro, Maria E. Pagano, Stefania Gori, Diana Giannarelli, Silvia Novello, Francesco Passiglia
Published 2025Artigo -
20
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program by Francesco Passiglia, Maria Lucia Reale, Giuseppe Lo Russo, Giulia Pasello, Gabriele Minuti, Alessandra Bulotta, Domenico Galetta, Giacomo Pelizzari, Claudio Sini, Emilio Bria, Elisa Roca, Sara Pilotto, Carlo Genova, Giulio Metro, Fabrizio Citarella, Rita Chiari, Diego Cortinovis, Angelo Delmonte, Alessandro Russo, Marcello Tiseo, Giulio Cerea, Annamaria Carta, Vieri Scotti, Tiziana Vavalà, Marta Brambilla, L Buffoni, Roberta Buosi, Chiara Catania, Stefania Gori, Salvatore Grisanti, Francesco Agustoni, Edoardo Garbo, Umberto Malapelle, Silvia Novello
Published 2023Artigo
Search Tools:
Related Subjects
Medicine
Internal medicine
Cancer
Oncology
Lung cancer
Immunotherapy
Biology
Chemotherapy
Pembrolizumab
Adverse effect
Biochemistry
Clinical trial
Colorectal cancer
Confidence interval
Nivolumab
Cancer research
Cohort
Hazard ratio
KRAS
Progression-free survival
Discontinuation
Epidermal growth factor receptor
Gastroenterology
Metastasis
Overall survival
Retrospective cohort study
Biomarker
Breast cancer
Chemistry
Disease